Navigation Links
New Book Highlights Human Cost of FDA's Failure to Investigate Medical Devices
Date:5/28/2009

NEW YORK, May 28 /PRNewswire-USNewswire/ -- A new history of shock treatment (electroconvulsive therapy, or ECT) - "Doctors of Deception: What They Don't Want You to Know About Shock Treatment" (Rutgers University Press) - reveals the human costs of the Food and Drug Administration's failure to investigate the devices that administer this controversial treatment for mental illnesses. The book is timely due to the FDA's recent decision to call on the manufacturers of the ECT device - and all high-risk Class III medical devices that were "grandfathered" in without the scientific testing that would be required today - to prove that it is safe and effective.

"The FDA has allowed shock machines to be used for 33 years without any evidence of their safety," said Linda Andre, the book's author and director of the Committee for Truth in Psychiatry, a national organization of former shock patients. Manufacturers of Class III devices may have to pay for costly clinical trials for devices that are already on the market, unless they can convince the FDA to change their classification to less risky, the Wall Street Journal reports. "If the manufacturers cannot provide such evidence, the agency is supposed to take the devices off the market," Andre said.

The FDA has known since 1979 that ECT poses serious risks, including brain damage and permanent memory loss. Andre's book chronicles the decades-long battle between former patients harmed by shock treatment and organized psychiatry over whether the shock machine should be investigated for safety, and includes first-person accounts from patients who were, Andre says, "guinea pigs for an untested device."

These patients formed their own organization to petition the FDA for brain-scan studies and for a consent form informing potential ECT patients of the known risks of ECT, and offered their own brains for study. They were joined by thousands of concerned citizens in a simple plea: If shock treatment is as safe as the American Psychiatric Association claims, why not investigate it?

In the past, bending to pressure from the APA, the FDA refused to conduct its own studies or require the manufacturers to prove safety. The agency said it would, instead, simply declare the device safe by reclassifying it as low risk (Class II).

"That is still the likeliest outcome," warns Andre.

Contact: Linda Andre, Committee for Truth in Psychiatry, 917-642-4625; ctip@rcn.com


'/>"/>
SOURCE Committee for Truth in Psychiatry
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Stanford study highlights cost-effective method of lowering heart disease risks
2. REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
3. Other highlights in the September 11 JNCI
4. NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue
5. Georgia Pecans Fit!: New Campaign Highlights Health Benefits, Recipes, Web Site
6. Highlights from the October 2007 Journal of the American Dietetic Association
7. Stereotaxis Highlights New Data on Acute Success in AFib Treatments With Niobe Magnetic Navigation System
8. NEWSWEEK International Editions: Highlights and Exclusives, OCT. 15, 2007 Issue
9. Study Highlights Impact of Chronic Conditions on Working America
10. Report highlights inadequate pandemic planning as a threat to EU security
11. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... For over twenty-four years, Doctors on Liens has published a directory of the ... medical care. When the company started in 1997, the directory was a single page ... the now ten-page directory features a vast array of medical specialists stretching from ...
(Date:12/2/2016)... ... 02, 2016 , ... FlexiSpot, a trusted name in sit-stand ... program for all of the company’s desktop riser products. A simple application form ... , FlexiSpot’s unique desktop risers use an advanced dual gas spring hovering system ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the ... how he was inspired to practice medicine at an early age by his father, ... than making diagnoses and prescribing medicine,” he states. “It is about building relationships with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, ... through labeling, storing, shipping and disposal. The new version is a faster and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Md. , Dec. 2, 2016 The ... indication for Jardiance (empagliflozin) to reduce the risk of ... mellitus and cardiovascular disease. "Cardiovascular disease ... type 2 diabetes mellitus," said Jean-Marc Guettier , ... Endocrinology Products in FDA,s Center for Drug Evaluation and ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
(Date:12/2/2016)... , December 2, 2016 ... Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), ... (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast ... is valued at USD 60.22 Billion in 2016. ... CAGR of 5.5% during the forecast period (2016-2021) ...
Breaking Medicine Technology: